Sugi Predict

Sugi Predict / Targets / POU2F1

POU2F1

POU domain, class 2, transcription factor 1 · P14859 · POU2F1 on Sugi Atlas →

1,901 patent compounds predicted against POU2F1, 1,800 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Linagliptin Linagliptin (SCHEMBL160188) 1.00 1/20
Linagliptin Linagliptin (SCHEMBL195962) 1.00 1/20
Linagliptin Linagliptin (SCHEMBL637238) 1.00 1/20
SCHEMBL1771687 SCHEMBL1771687 0.88 1/20
SCHEMBL1771688 SCHEMBL1771688 0.88 1/20
SCHEMBL638034 SCHEMBL638034 0.87 1/20
SCHEMBL639186 SCHEMBL639186 0.87 1/20
SCHEMBL639382 SCHEMBL639382 0.86 1/20
SCHEMBL637704 SCHEMBL637704 0.85 1/20
SCHEMBL637705 SCHEMBL637705 0.85 1/20
SCHEMBL639200 SCHEMBL639200 0.85 1/20
SCHEMBL1772110 SCHEMBL1772110 0.85 1/20
SCHEMBL1772111 SCHEMBL1772111 0.85 1/20
SCHEMBL1772935 SCHEMBL1772935 0.85 1/20
SCHEMBL1772936 SCHEMBL1772936 0.85 1/20
SCHEMBL3548872 SCHEMBL3548872 0.85 1/20
SCHEMBL3548877 SCHEMBL3548877 0.85 1/20
SCHEMBL1771774 SCHEMBL1771774 0.84 1/20
SCHEMBL1771776 SCHEMBL1771776 0.84 1/20
SCHEMBL637993 SCHEMBL637993 0.84 1/20

Clinical trials — most relevant to POU2F1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome PHASE4WITHDRAWN
Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation PHASE2/PHASE3UNKNOWN
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer PHASE1/PHASE2SUSPENDED
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial) PHASE2RECRUITING
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma PHASE1WITHDRAWN
Induced Pluripotent Stem Cell Derived Exosomes for the Treatment of Atopic Dermatitis EARLY_PHASE1UNKNOWN
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy nanNOT_YET_RECRUITING
Patient Specific Induced Pluripotency Stem Cells (PSiPS) nanCOMPLETED
Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases nanRECRUITING
EKLF Gene Expression in β-thalassemia nanNOT_YET_RECRUITING
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
The Role of TBX3 in Human ES Cell Differentiation nanWITHDRAWN
Study of Neurodegenerative Diseases Induced Stem Cells in Patients and Healthy Family Controls. nanUNKNOWN
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome nanRECRUITING
MR Elastography in Intracranial Lesions: Feasibility & Accuracy nanACTIVE_NOT_RECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Effect of Post Covid-19 Hypoxia on Placenta of Normal Pregnant Women: A Possible Role of Hypoxia Inducible Factor-1α. nanUNKNOWN
Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells nanRECRUITING
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Natural History of Thyroid Function Disorders nanRECRUITING
Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Production of Stem Cells for the Generation of Pancreatic Cells nanRECRUITING
Azoospermia Patients nanRECRUITING
Transcription Factor Runx2 in Necrotic Femoral Head Tissue nanCOMPLETED
Prognostic Value of Protein IMP3 Expression in Cervical Cancer nanCOMPLETED
Cell Collection to Study Eye Diseases nanRECRUITING
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy nanRECRUITING
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a POU2F1 binder may also engage these)

ProteinNameSimilarity
P15143 — 1.000 P15143 →
P25425 — 1.000 P25425 →
Q29076 — 1.000 Q29076 →
P16143 — 1.000 P16143 →
P31503 — 1.000 P31503 →
Q28BL7 — 1.000 Q28BL7 →
ATF1 Cyclic AMP-dependent transcription factor ATF-1 0.993 landscape →
Q4VYS1 — 0.992 Q4VYS1 →
CREB1 Cyclic AMP-responsive element-binding protein 1 0.991 landscape →
Q01147 — 0.991 Q01147 →
Q58NQ4 — 0.991 Q58NQ4 →
Q08DA8 — 0.991 Q08DA8 →
P0CF24 — 0.991 P0CF24 →
Q03061 — 0.991 Q03061 →
Q5QL03 — 0.991 Q5QL03 →
Q86NP2 — 0.991 Q86NP2 →
Q8HZ00 — 0.991 Q8HZ00 →
Q498D1 — 0.990 Q498D1 →
Q62445 — 0.990 Q62445 →
Q0IHV2 — 0.990 Q0IHV2 →
Q10572 — 0.989 Q10572 →
P15337 — 0.989 P15337 →
Q5E9U0 — 0.989 Q5E9U0 →
Q90867 — 0.989 Q90867 →
Q9H334 — 0.989 Q9H334 →
Q9D2H6 — 0.989 Q9D2H6 →
Q1LZH5 — 0.989 Q1LZH5 →
P81269 — 0.989 P81269 →
P52655 — 0.989 P52655 →
Q03372 — 0.989 Q03372 →